THE TUMOR NECROSIS FACTOR-A-308 G/A POLYMORPHISM AND THE TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND POLYMORPHISMS, IN ASTHMATIC PATIENTS AND HEALTHY SUBJECTS

Basit Öğe Kaydı
dc.contributor.authorIsi, H.
dc.contributor.authorOral, D.
dc.contributor.authorYildiz, T.
dc.contributor.authorAtes, G.
dc.contributor.authorSinir, C.
dc.contributor.authorAy, O. I.
dc.contributor.authorTurkoz, G.
dc.date.accessioned2024-04-24T17:20:21Z
dc.date.available2024-04-24T17:20:21Z
dc.date.issued2010
dc.departmentDicle Üniversitesien_US
dc.description.abstractAsthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. Like other atopic diseases, asthma is a complex disorder caused by interactions between multiple genes of small to modest effect and equally important environmental factors. The aim of this study was to determine the TNF-alpha-308 G/A polymorphism and the TRAIL polymorphisms, and their influence on asthma in asthmatic patients and healthy subjects. The study population consists of 51 asthmatic patients (47 female and 4 male) and 72 healthy subjects (62 female and 10 male). The mean age of the asthmatic patients and healthy controls were 45.33+/-14.05, and 41.88+/-17.41 years, respectively. The asthmatic patients and healthy controls were similar with respect to their ages and sex characters. There was statistically a significant difference between the asthmatic patients and control groups in terms of TRAIL Arg141His, G422A (rs6557634) polymorphism (p=0.02). Statistically, there was not any significant difference between the asthmatic patients and control groups for TRAIL Thr209Arg, C626G (rs20575) TRAIL Glu228Ala, A683C (rs20576) and polymorphisms (p=0..57). Also, there was no significant difference between the asthmatic patients and control groups in terms of TNF-alpha-308 G/A polymorphism (p=0.90). In our study, the TRAIL Arg141His G422A (rs6557634) polymorphism was detected for the first time in asthmatic patients, which may influence the susceptibility to the asthma.en_US
dc.identifier.doi10.2478/V10133-010-0018-2
dc.identifier.endpage1643en_US
dc.identifier.issn1310-2818
dc.identifier.issn1314-3530
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-77950156074
dc.identifier.scopusqualityQ3
dc.identifier.startpage1638en_US
dc.identifier.urihttps://doi.org/10.2478/V10133-010-0018-2
dc.identifier.urihttps://hdl.handle.net/11468/18962
dc.identifier.volume24en_US
dc.identifier.wosWOS:000276230500018
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofBiotechnology & Biotechnological Equipment
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAsthmaen_US
dc.subjectGenetic Polymorphismen_US
dc.subjectTnf-Alphaen_US
dc.subjectTrailen_US
dc.titleTHE TUMOR NECROSIS FACTOR-A-308 G/A POLYMORPHISM AND THE TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND POLYMORPHISMS, IN ASTHMATIC PATIENTS AND HEALTHY SUBJECTSen_US
dc.titleTHE TUMOR NECROSIS FACTOR-A-308 G/A POLYMORPHISM AND THE TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND POLYMORPHISMS, IN ASTHMATIC PATIENTS AND HEALTHY SUBJECTS
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu